APAC Healthcare Weekly (Aug 3)– Celltrion, Alteogen, Wuxi Bio, CSPC, Jiangsu Hengrui, Eisai, Kissei

481 Views03 Aug 2025 08:30

Celltrion is acquiring a biopharmaceutical production plant in US. Wuxi Bio starts construction of new facility. CSPC and Jiangsu Hengrui stuck outlicensing deals for GLP-1 and COPD drug candidates.

What is covered in the Full Insight:

Celltrion's U.S. Expansion
Alteogen's Biosimilar Approval
Wuxi Biologics' Singapore Facility
Sarepta's Regulatory Challenges
Upcoming Earnings and Events

Tina Banerjee

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 5-minute read)

Discussions

(Paid Plans Only)

Insight Stream